KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables RefundsShares IssuedShares OutstandingShares Repurchased
Ratios

Sarepta Therapeutics (SRPT) Accumulated Depreciation & Amortization: 2011-2024

Historic Accumulated Depreciation & Amortization for Sarepta Therapeutics (SRPT) over the last 1 years, with Dec 2024 value amounting to $234.1 million.

  • Sarepta Therapeutics' Accumulated Depreciation & Amortization rose 22.61% to $234.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $686.6 million, marking a year-over-year increase of 29.92%. This contributed to the annual value of $37.7 million for FY2024, which is 15.03% down from last year.
  • Per Sarepta Therapeutics' latest filing, its Accumulated Depreciation & Amortization stood at $234.1 million for Q4 2024, which was up 22.61% from $191.0 million recorded in Q4 2023.
  • Sarepta Therapeutics' 5-year Accumulated Depreciation & Amortization high stood at $234.1 million for Q4 2024, and its period low was $76.0 million during Q4 2020.
  • Its 3-year average for Accumulated Depreciation & Amortization is $191.3 million, with a median of $191.0 million in 2023.
  • Data for Sarepta Therapeutics' Accumulated Depreciation & Amortization shows a peak YoY spiked of 49.09% (in 2020) over the last 5 years.
  • Over the past 5 years, Sarepta Therapeutics' Accumulated Depreciation & Amortization (Quarterly) stood at $76.0 million in 2020, then spiked by 48.15% to $112.6 million in 2021, then spiked by 32.18% to $148.9 million in 2022, then increased by 28.27% to $191.0 million in 2023, then climbed by 22.61% to $234.1 million in 2024.
  • Its last three reported values are $234.1 million in Q4 2024, $191.0 million for Q4 2023, and $148.9 million during Q4 2022.